The US FDA have notified the Austrian biotech company Activartis that Orphan Drug Designation (ODD) has been granted for its innovative Cancer Immunotherapy AV0113. The ODD applies specifically to the use of AV0113 for the treatment of malignant glioma, a very aggressive type of brain cancer. The European drug agency EMA already granted ODD at the end of last year. In principle, Activartis' AV0113 Cancer Immunotherapy may be used to fight any type of cancer...
More...
More...